» Articles » PMID: 24876207

Evaluation of Cobalt-labeled Octreotide Analogs for Molecular Imaging and Auger Electron-based Radionuclide Therapy

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2014 May 31
PMID 24876207
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The somatostatin receptor, which is overexpressed by many neuroendocrine tumors, is a well-known target for molecular imaging and peptide receptor radionuclide therapy. Recently, (57)Co-labeled DOTATOC, an octreotide analog, was shown to have the highest affinity yet found for somatostatin receptor subtype 2. The aim of this study was to evaluate the biologic effects of novel cobalt-labeled octreotide analogs targeting the somatostatin receptor to identify promising candidates for molecular imaging and Auger electron-based radionuclide therapy.

Methods: Cobalt-labeled DOTATATE, DOTATOC, and DOTANOC were prepared with (57)Co or (58m)Co for SPECT or Auger electron-based therapy, respectively. The cellular uptake and intracellular distribution of the radioligands were characterized with the pancreatic tumor cell line AR42J in vitro, including assessment of the therapeutic effects of (58m)Co-DOTATATE via DNA double-strand break and proliferation assays. Comparisons with the therapeutic effects of (111)In- and (177)Lu-DOTATATE were also performed. Tumor uptake and normal tissue uptake were characterized in a subcutaneous pancreatic tumor mouse model.

Results: All 3 cobalt-conjugated peptides resulted in time-dependent and receptor-specific uptake, with a high level (≥88%) of cellular internalization in vitro of the total cell-associated radioactivity. The DNA double-strand break yield showed a dose-dependent increase with activity, whereas cell survival showed a dose-dependent decrease. (58m)Co-DOTATATE was significantly more efficient in cell killing per cumulated decay than (111)In- and (177)Lu-DOTATATE. The in vivo pharmacokinetic studies showed a high level of receptor-specific tumor uptake.

Conclusion: All cobalt-labeled radioligands showed a high level of receptor-specific uptake both in vitro and in vivo in tumor-bearing mice. Furthermore, (58m)Co-DOTATATE showed considerable therapeutic effects in vitro and, thus, could be an effective agent for eradicating disseminated tumor cells and micrometastases.

Citing Articles

Side-by-Side Comparison of the In Vivo Performance of [Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds.

Saidi A, Stallons T, Wong A, Schatzmann A, Soysal U, Torgue J J Nucl Med. 2025; 66(3):391-397.

PMID: 39884771 PMC: 11876737. DOI: 10.2967/jnumed.124.268345.


Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.

Ge L, Danielsen M, Nielsen A, Skavenborg M, Langkjaer N, Thisgaard H Molecules. 2025; 30(2).

PMID: 39860082 PMC: 11767697. DOI: 10.3390/molecules30020212.


Preclinical evaluation of [Co]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer.

Baun C, Dam J, Hildebrandt M, Ewald J, Kristensen B, Gammelsrod V Sci Rep. 2023; 13(1):18837.

PMID: 37914790 PMC: 10620164. DOI: 10.1038/s41598-023-43429-8.


Separation of cyclotron-produced cobalt-55/58m from iron targets using cation exchange chromatography with non-aqueous solvents and extraction chromatography.

Lin W, Aluicio-Sarduy E, Barrett K, Barnhart T, Mixdorf J, DeLuca M Appl Radiat Isot. 2023; 200:110980.

PMID: 37591186 PMC: 10529958. DOI: 10.1016/j.apradiso.2023.110980.


Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.

Lin W, Aluicio-Sarduy E, Houson H, Barnhart T, Tekin V, Jeffery J Nucl Med Biol. 2023; 118-119:108329.

PMID: 36805869 PMC: 10121947. DOI: 10.1016/j.nucmedbio.2023.108329.